Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov) - Jul 27, 2023 - P1/2 | N=3 | Terminated | Sponsor: German Cancer Research Center | N=86 ➔ 3 | Trial completion date: Sep 2025 ➔ May 2023 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ May 2023; premature termination of the trial due to bad recruitment
Checkpoint inhibition • Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Trial termination • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FOLH1
|